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ABSTRACT OF THESIS

STABILITY OF AFFINITY BASED LAYER-BY-LAYER POLYMERIC SELF-ASSEMBLIES FOR ORAL
WOUND APPLICATIONS
Oral mucositis is a painful and debilitating chronic inflammatory condition that can
result from chemo and/or radiotherapy. While current treatment strategies which
provide temporary relief exist, there is still an unmet clinical need for a robust long
active barrier strategy which can simultaneously provide protection and release drug to
enhance the wound healing response. It is proposed that an affinity based layer-by-layer
self-assembled barrier administered as a series of mouth rinses can allow for wound
specific drug delivery, providing an effective regenerative therapy.
In this work, biotinylated poly(acrylic acid) is used to develop LBL assemblies based upon
biotin-streptavidin affinity interactions. To explore the ability of developed LBL
assemblies to resist the harsh intraoral environment, in vitro chemical and ex vivo
mechanical tests are performed. The stability results demonstrate significant LBL barrier
stability with wear resistance. From principal component regression analysis, factors
such as polymer MW and number of layers in assemblies contributed significantly to
chemical barrier stability. Also it is observed that the extent of biotin conjugation plays a
significant role in LBL development and in mechanical stability. Thus, the proposed
affinity based multilayered assemblies with their excellent barrier properties offer a
modular treatment approach in oral mucosal injuries.
KEYWORDS: Oral mucositis, Biotin-Streptavidin, Layer-by-Layer, Poly (acrylic acid), Oral
drug delivery
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CHAPTER 1.

INTRODUCTION

Oral mucositis (OM), an inflammatory ulcerous oral wound condition, is a
commonly occurring side-effect of anti-cancer therapies, including chemotherapy
and/or radiotherapy [1]. This debilitating acute pathology causes severe pain leading to
dysphasia and impacts patients overall quality of life [2-4]. Every year in the United
States, approximately 132,000 patients undergoing anti-cancer therapies develop OM
(as per 2003 data) [5, 6]. More than 90% of patients subjected to head and neck cancer
therapies (HNC) develop OM, with the estimated cost per patient exceeding $17,000
(USD) [4, 7-9].
Current strategies employed in OM treatment are similar to methods used for
dermatological cases such as oral gels or lubrication mouth rinses that can provide only
a temporary palliative relief with poor patient compliance [6, 10]. In order to overcome
the inadequacies in current treatment methods, a modular treatment strategy is
proposed utilizing biotin-streptavidin affinity linkages for developing multilayered
polymeric self-assemblies. It is hypothesized that a targeted layer-by-layer (LBL)
polymeric self-assembly developed over the oral wound surface will offer a desired
regenerative treatment strategy through its stable barrier effects. Hence, evaluating the
barrier stability of LBLs against the harsh intraoral environment is a key requirement to
validate its application in oral wounds.
In this work, in vitro chemical stability tests are performed by studying the
proteolytic effects of unstimulated whole saliva (UWS) and protease (pronase) on LBL
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assemblies. Through chemical stability tests, destabilization of self-assembled layers is
evaluated. Statistical analyses (multivariate analysis and ANOVA models) are performed
to identify key factors (polymer molecular weight / biotin conjugation / number of
assembly layers), contributing to LBL chemical stability. Developing an understanding of
the key factors that control LBL chemical stability is instrumental in formulating a
tunable LBL system with desired barrier properties. In order to study LBL barrier
durability and wear resistance, ex vivo mechanical tests (adhesion tests) are performed.
Porcine patches are used as a model tissue substrate for developing LBL assemblies in
adhesion tests. A repeat contact barrier fatigue test is performed on LBL developed on
tissue substrate to determine the extent of LBL barrier loss (wear resistance) from
repeated loading cycles (load-pull offs).
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CHAPTER 2.

BACKGROUND

2.1. Problem Statement
Oral mucositis, a painful and debilitating oral wound condition, is a frequently
occurring post-operative complication in anti-cancer therapies such as radiotherapy,
chemotherapy, chemoradiotherapy and hematopoietic stem cell transplants (HSCT) [1114]. OM is manifested by erythema and inflammatory lesions, which rupture through
the oral epithelial mucosal walls [1, 15]. This mucosal barrier injury causes severe pain
with loss of oral functionality, thereby resulting in reduced nutritional uptake and
dysphasia [4, 16, 17].
OM compromises the patient’s overall quality of life by not only affecting routine
functions, such as eating, swallowing or speaking but also through its high cost for
treatment and care [18]. Invariably, affected patients experience an increased duration
of hospital care, adding to the economic burden of their treatment. This was
exemplified in literature studies[19, 20], which showed that patients with OM induced
by autologous transplants required an additional hospitalization time of at least 5 days,
which contributed to an expenditure of $22,500/ patient. A study conducted by Sonis et
al. [21] about economic outcomes of OM in HSCT patients report a total hospital charge
of $42,479 higher than patients who do not develop OM. Also, in patients suffering from
OM, there is an increased risk of infection through colonization of bacterial flora, which
aggravates the existing oral wound condition. Finally, OM can interrupt cancer
treatment, a result of apoptotic response and cellular death from radiation or
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chemotherapeutic doses. This affects patient’s treatment regime and possess a
potential risk of death from treatment delays [22].
Despite such serious effects of OM and its impact in patients life, the use of
potent anti-cancer therapies and administrating aggressive treatment regimes has
become an inescapable part of cancer treatment and control [23]. Hence, it is
unsurprising to observe high incidence rates of OM, where nearly 30%-75% patients
subjected to chemotherapy and 70% - 90% of bone marrow recipients are affected [1,
13, 17]. The incidence rate of OM was found to be even more for head and neck
radiotherapy, greater than 90 % [4, 7].
2.2. Risk factors
The incidence of OM and its severity can be described by two broad categories,
treatment related and patient related factors. Subcategories under treatment related
factors include type of cancer treated, treatment method employed, dosage, and
treatment regimes. In patient related factors, variables such as oral hygiene, age and
gender can affect OM incidence, severity and the disease duration [1, 20, 24].
2.2.1. Treatment related factors
Among treatment factors, the risk among cancer types is highly dependent on
the zone of treatment, where cancer treatment involving head and neck regions have
been found to be more susceptible to development of ulcerous lesions. In contrast, a
relatively low risk is found among treatments in other regions [25]. Also, the incidence
of severe OM is frequent among patients subjected to conditioning therapy after bone
marrow transplants (>60%) [20, 26-28].

4

Interestingly, from a study of 150 patients, there is a reported high frequency (1
in 3 incidence) of mucositis (mild to severe) due to the chemotherapeutic effect on solid
tumors, emphasizing the potential treatment impact [25]. Among patients subjected to
high dose chemo/radiotherapy regimes, the incidence rate of OM and its extent of
severity increases. Repeated low chemotherapeutic dosages also possess a high risk as
when compared to bolus infusion. Hence, apart from dosage factors the number of
cycles that was previously administered also affect the risk of OM incidence[28].
In radiotherapy induced OM, various factors such as irradiated mucosal volume,
dose intensity, applied cumulative dosage and other dietary factors such as smoking or
drinking prior to treatment can have an impact on disease severity and its duration [2830]. For the standard dose of 200 centi-Gray/day onset of erythema can be seen within
a week of treatment, which on accumulating cumulative total dose of 1600-2000 cGy
will result in atrophy of oral epithelial walls [28, 31-33]. Such irradiations can also
damage salivary glands, resulting in xerostomia (hyposalivation), where the resulting
oral dryness worsens the existing condition due to lack of essential salivary functions
such as oral lubrication, regulation of acidity and mucosa protection [33, 34].
2.2.2. Patient related factors
In patient related factors, the existing wound condition can be exacerbated by
maintaining poor oral hygiene, which causes excessive oral flora and increased infection
rate [17, 33, 35]. Age also impacts the rate of OM. The frequency of OM incidence is
higher among younger people (<20 years), a result of greater number of rapidly dividing
mitotic cells (basal cell proliferation) [15, 33]. In older people (age >50), the developed
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mucositis is more severe, necessitating greater healing time[15]. OM incidence during
chemotherapy is also increased among patients with poor nutritional status or reduced
food uptake during the treatment regime. Interestingly, patients with low body mass
index (BMI<20) were found to be more susceptible to developing OM [25, 36].
2.3. Pathobiology of oral mucositis
The development of OM can be broken down into 5 key stages, as described by
Sonis et. al., [37].
1) Initiation
2) Primary damage response (Upregulation and message generation)
3) Signal amplification
4) Ulceration and
5) Healing
It should be noted that while these stages are conceptually separated for ease of
understanding, the pathological process in OM is dynamic, where the phases can be
overlapping depending upon the adopted treatment procedure[38]. For instance, during
radiotherapy when patients receive small doses for an extended duration, they
invariably develop chronic damage which results in staged overlaps. In contrast, patients
subjected to chemotherapy receive short and intensive bolus injections resulting in an
acute damage with relatively better distinguished stages [37].
1) Initiation
Initiation is the inflammatory phase, also commonly referred to as “initial
tissue injury phase”, whose onset occurs rapidly after administering chemotherapy
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and/or radiotherapy [13, 37]. This stage is predominately marked by the generation of
reactive oxygen species (ROS), resulting in oxidative stress. Here, it is not the initial
direct tissue damage (DNA and non-DNA damage) but the generation of ROS that
results in extensive tissue damage [39]. This oxidative stress upregulates inflammatory
signaling molecules (e.g. nuclear factor- κB) and biological pathways, and leads to
primary damage response which contributes to mucosal damage [4, 37].
2) Primary damage response
In a series of cascading events, ROS activates various transcription factor and
multiple pathways, such as nuclear factor-κB (NF- κB), STAT3 (signal transducer and
activator of transcription 3), p53 (tumor protein 53), and the ceramide pathway [13, 37,
38, 40]. Ceramides (sphingolipids in the form N-acylated sphingosine) were found to be
abundant in cell membranes which in response to cellular stress activates several
enzymes (e.g. cathepsin D, serine protein phosphatases). Such activation regulates
different pathways eventually leading to growth inhibition or cellular death [40].
NF-κB is considered a central player with its ability to upregulate ~200 genes,
whose expression can modulate cytokines production, cell adhesion molecules, stress
response genes and cyclooxygenease-2 pathway [38, 41]. NF-κB, effects both proapoptotic and anti-apoptotic response, greatly influencing the fate of normal tissues and
effectiveness of cancer treatment [37].
Such upregulation of genes due to transcription factor activation induces
production of pro-inflammatory cytokines, including tumor-necrosis factors (TNF-),
interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-1β (IL-1β) [37, 39]. The effect of pro-
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inflammatory cytokines along with apoptotic response from ceramide pathway
activation (a result of cellular stress from ROS generation) brings forth epithelial damage
and injury [37, 40]. Also, studies reported by Bamba et al [42], showed an upregulated
effect

of

cytokines on

activator

protein-1

(AP-1),

which

activates

matrix

metalloproteinases (MMPs) and contributes to tissue injury and inflammation [37, 43].
This effect was pronounced within submucosa, where MMPs disrupt the sub-epithelium
(due to MMP1, an interstitial/fibroblast collagenase) and epithelium basement (due to
MMP3, also called as Stromelysin-1) resulting in injury [37, 39].
3) Signal amplification
While cytokine production and pathway activation result in primary tissue
damage, such effects are further increased due to a signal amplification mechanism. In
signal amplification, the pro-inflammatory cytokines or protein from biological pathways
stimulate a positive feedback loop response, which increases the impact of primary
tissue injury [8, 39]. Such feedback mechanisms [44] follow a complex series of
interlinked networks. One such pro-inflammatory cytokine (TNF-) amplifies NF-κB
production, which in turn can upregulate various genes to produce more cytokines or
activate pathways to result in injury [38, 39]. As an illustration of the pathway of
activation, activated NF-κB results in more cytokines production, which affects ceramide
pathways and results in production of more MMPs, causing an eventual apoptotic
response [4, 39].
4) Ulceration
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As a result of loss of cells due to the apoptotic effects of preceding events,
the oral mucosal epithelium thins out, resulting in an ulcerative stage [4, 45]. For
example, during administration of chemotherapeutic doses, the onset of such ulcerous
lesion can usually be found within 14 days [45]. This mucosal barrier injury aided by lack
of epithelial proliferation becomes a zone of increased bacterial growth[39]. In response
to this increased bacterial growth and inflammation, there is an accompanying increase
in macrophages and neutrophils infiltration which further augments inflammation and
risk of septicemia (sepsis, bacteremia) [4, 8, 39]. Ruescher et al.,[46] illustrated the
increased incidence of bacteremia among OM patients undergoing autologous HSCT,
where there was an increase in streptococci infections. In addition, the cell wall products
released from such bacterial floras stimulates the production of pro-inflammatory
cytokines through immune pathways [4, 8]. Such release of cytokines, contributes to
existing signal amplification process which further debilitates the existing wound
condition by aggravating pain and injury.
5) Healing
The healing process commonly occurs within 2-3 weeks following the posttreatment (chemotherapy) process [47]. During the healing phase, down-regulation of
the inflammatory response is accompanied by extracellular matrix (ECM) signaling to
epithelial cells. ECM contains a complex structural network (fibrous protein,
proteoglycans and glycoproteins) which contributes to structural support of tissues [48].
Mesenchyme and ECM signal epithelial migration, proliferation and differentiation
which allows for epithelial wound healing [39]. Although such migrations help in
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remodeling superficial epithelial injuries, a complete recovery in zones of severe
necrosis or deep wounds require a combined effect with angiogenesis [45, 49]. Thus, the
duration of the healing phase can be highly dependent upon severity of oral mucositis
which in turn is a function of treatment and patient related factors (risk factors).
2.4. Oral mucositis Assessment Scales
Currently, the severity of OM is assessed using several scales including the World
Health Organization (WHO), National Cancer Institute (NCI), NCI Common Toxicity
Criteria (NCI CTC), Oral Mucositis Assessment Scale (OMAS) and Western Consortium for
Cancer Nursing Research (WCCNR) [1, 50]. Such scoring methods have been developed
which consider 1.) extent of functionality loss (e.g. dysphasia) 2.) patient’s subjective
factors (e.g. pain) and/or 3.) objective clinical indicators (e.g. infection) [51]. Detailed
biological evaluation employed for each of these scoring methods is listed in Table 2-1.
Despite the availability of such a variety of scoring methods, there is still a need for
commonly followed standard procedures with a capability to meet all desired criteria
[17].
To exemplify the debilitating condition of oral mucositis and thereby provide a
visual representation of grades involved in one such scoring method, an illustration
using NCI assessment scales is shown in Figure 2-1 (Cawley et.al). The current proposed
strategy suggested in this work is expected to offer a potential treatment solution for
OM with Grades 2, 3, and 4 (based on the NCI scale). Patients with grade-2 OM exhibit
the onset of patchy ulcerations whereas at grade-5 the ulcerations coalesce thereby
denude the mucosa. Despite such varied OM grades (2, 3, and 4), the common aspect
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between them is the degree of fibrin exposure resulting from epithelial disruption and
ulceration lesions. Such fibrin elements, a key component from exposed oral injury [52,
53] can be targeted by a complimentary fibrin binding peptide “CREKA” functionalized in
biotinylated polymer. CREKA (Cys-Arg-Glu-Lys-Ala) is a pentapeptide widely reported in
the literature for its effective fibrin targeting ability [54-58]. The targeted CREKA
functionalized polymeric layer forms an adhesive base layer over oral pathology. By
providing a series of alternating protein streptavidin and biotinylated polymer mouth
rinses, multilayered polymeric barrier systems (layer-by-layer (LBL)) can be developed
over the targeting layer, as shown in Figure 2-3.
2.5. Barriers in prevention or treatment of oral mucositis
One major hindrance in treating OM is due to the conventional belief among
health care providers that mucositis is solely a result of damage to the rapidly dividing
oral epithelial walls. However, with recent greater understanding of the pathobiological
mechanism of OM, there is a huge future potential for developing better
pharmacological products utilizing a mechanistic based treatment approach [17, 37, 39,
59]. Such mechanistic based treatment approaches under clinical investigation
predominantly function by modifying the biological responses (e.g. keratinocyte growth
factor or epidermal growth factor).
With current treatments being similar to those adapted for dermatological cases,
there is a need for better redesigned approaches specifically tailored for oral mucosal
applications. Oral mucosa exists in a complex environment where they are subjected to
continual salivary flushing activity. Although salivary action helps to provide a hydrating
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medium for drug distribution, such effects could also result in rapid drug clearance by
swallowing [60, 61]. In overcoming such drawbacks, a drug delivery device should be
capable of minimizing salivary dilution effects thereby potentially obviating the need for
repeated drug dosing [60]. Another major block in developing oral mucosal delivery
systems is the harsh intra-oral environment, which characteristically possesses exuding
fluids, mastication and proteolytic degradation effects, which present unique challenges
in developing an effective drug carrier for periodontal drug delivery [60] (Figure 2-2).
2.6. Preventive Strategies
To address OM, a prophylactic strategy would be an ideal treatment method, but
in reality such prevention is hardly possible [17, 62]. Prophylactic methods using nontherapeutic methods such as oral cryotherapy (minimizing effect of OM due to
chemotherapy), low-intensity lasers, midline radiation blocks, and three-dimensional
radiation treatment (to reduce OM from radiation therapy) are often recommended in
preventing OM[1, 7]. A more detailed description of various preventive strategies (nontherapeutic methods) is provided in Table 2-2.
Recently, the use of topical analgesics is often suggested as an alternative
method. The majority of such analgesics function by inhibiting pro-inflammatory
cytokine production. Such down-regulation results in pain reduction and brings forth an
anti-inflammatory effect. A more detailed review on various topical analgesics is listed in
Table 2-3.
With recent greater understanding about pathophysiology of OM as described
earlier, the use of biological response modifiers in prophylaxis has been widely
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investigated. Such prevention was a result of modification in key factors controlling
disease severity such as downregulation of cytokine production or upregulating
epithelial proliferation and/or positively influencing angiogenesis process. A review of
various biological response modifiers is listed in Table 2-4. While the use of these
prophylactic methods reduced the impact of mucosal injuries, consensus has not been
reached on protocols and easily adopted and tolerated delivery strategies are needed
before they gain wide acceptance.
2.7. Current treatment Strategies
The majority of the current treatment methods focus on symptom management
rather than providing regenerative therapy. Various topical treatment methods, [63]
being adopted or under investigation involve formulation such as,
1) Oral mouth rinses - e.g. MuGuardTM and Caphosol® [64]
2) Bioadherent gels - e.g. Gelclair® [65]
3) Oral sprays
e.g. recombinant human intestinal trefoil factor (rhITF) oral spray [66] and
recombinant human epidermal growth factor (rhEGF) sprays [67]
4) Patches - e.g. flurbiprofen tooth patch[68]
5) Tablets - e.g. Xylocaine buccal tablets
Oral mouth rinses are quite common as a treatment strategy and are
predominantly non-targeted in their mode of treatment. They function by providing a
moistening effect, which enables rapid pain relief and prevents oral dryness
(Xerostomia). Caphosol© (a supersaturated calcium phosphate solution) is an example
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of one such oral mouth rinse, which prevents oral dryness through its lubricative effect
and thereby offers a temporary palliative effect. Another commonly used oral mouth
rinse is “magic mouth wash”, a combination of multifunctional ingredients such as
antibiotic, antihistamine, antifungal, steroid, local anesthetic or antacid [69]. This
multifunctional formulation was found to be ineffective in treating OM, likely a result of
the lack of any targeting and drug localization capacity, and therefore had therapeutic
value equivalent to a non-therapeutic saline mouth wash [17, 70, 71]. In treating OM, a
few commonly desired therapeutic effects involve: anti-inflammatory, analgesic (e.g.
benzydamine), topical anesthetic (e.g. lidocaine) and antimicrobial properties (e.g.
chlorhexidine) [3, 59]. Studies evaluating efficacy of various oral mouth rinses with such
ingredients either independently or in combination are quite prevalent. A more detailed
list on various oral mouth rinses is provided in Table 2-5.
Much of the exciting recent work on OM has focused on developing oral
bioadhesive films and gels for localized drug delivery [72-74]. Bioadhesive topical films
(e.g. hydroxypropyl-cellulose (HPC) based film (Zilactin)) function primarily through their
protective barrier effects over oral ulcerations and thereby provide temporary pain
relief [3]. Gelclair, a commonly used mucoadherent gel (polyvinylpyrrolidone, sodium
hyaluronate formulation), functions by providing a lubricative moistening effect [17].
Although most of the mucoadhesive gels help in providing rapid pain relief, such effects
are temporary. A detailed list of different mucoadhesive gels is provided on Table 2-6.
Unfortunately, patients suffering from OM invariably develop a highly irregular mucosal
surface from extensive ulcerous sores (occupying >50% of the oral cavity [3]) making

14

application of such bulky films and gels difficult, especially along the gumline. Hence,
with such current ineffective treatment methods, there is still a clinical need for an
improved treatment strategy for oral mucosal disease.
2.8. Proposed Modular Treatment Strategy
To achieve an effective OM therapy, it is desired to develop a strategy which can
1.) specifically target oral wound surfaces, 2.) prevent oral dryness by maintaining a
lubricative surface, 3.) effectively provide long term controlled release of antiinflammatory and wound healing agents, 4.) resist bacterial invasion, 5.) minimize pain
and inflammation, 6.) be durable to the chemical, mechanical environment and 7)
promote regenerative therapy to enable shorter healing times. (see Figure 2-2)
In this work, it is hypothesized that a modular layer-by-layer (LBL) polymer film
formed in situ can be designed to meet these goals. Through a series of oral mouth
rinses utilizing biotin-streptavidin affinity linkages, a multilayered polymeric system can
be developed as illustrated in Figure 2-3. The current proposed treatment strategy is
expected to provide significantly better barrier function to overcome shortcomings seen
from bulky bioadherent film/gel systems. The formulated multilayered barriers are
expected to be unaffected under intra-oral environments and remain wear resistant by
utilizing strong affinity-based linkages. Such multilayered polymeric systems (LBL), by
offering a protective stable barrier effect, enhance the regenerative wound healing
response among affected patients. Also, the potential ability of LBL systems to function
as a drug carrier vehicle can be used for oral delivery applications.
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The objective of this work is to evaluate the hypothesis that multilayered
systems can provide a desired long lasting barrier effect with a potential ability to
deliver drugs localized to oral mucosal wounds. Yet, in order to realize this, a LBL system
must both be chemically and mechanically stable. In this work, LBL barriers are formed
and evaluated for their in vitro stability in protease and salivary fluids. Further, to
demonstrate their ability to decrease surface interaction, ex vivo adhesions studies are
performed.
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Table 2-1: Evaluating severity of oral mucositis - various scoring methods with their employed method of assessment.

Oral Mucositis
scoring method

NCI-CTC
(for
chemotherapy)

NCI- CTC
(for
radiotherapy)

References

Grade 0

Grade 1

Grade 2

Grade 3

Grade 4

None

Soreness,
erythema

Erythema,
ulcer
can uptake
solid foods

Ulcer, can uptake only
liquid diet

Impaired/ inability to
provide any oral
nourishment

Erythema,
painless
ulcers, mild
soreness,
without
lesions

Painful
erythema,
ulcers but
possess ability
to eat or
swallow

Painful erythema,
edema, ulcers,
inability to eat
thereby requires
intravenous hydration

Severe ulceration,
require nutritional
support or
prophylactic
intubation

[28, 51]

Confluent pseudomembranous patches
(diameter >1.5 cm)

Necrosis, deep
ulceration, may
include bleeding not
induced by minor
trauma or abrasion

[28, 50, 76]

None

None

Erythema

Patchy
pseudomembranous
patches
(diameter ≤
1.5 cm)

[28, 75]
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WHO

Grades/ Scores/ Stages

Table 2-1 (Continued)

NCI- CTC
(for bone
marrow
transplants)

Oral Mucositis
Assessment
Scale (OMAS)

None

Erythema,
painless
mild
soreness,
without
lesions

Painful erythema,
Severe ulceration
edema, ulcers
requires prophylactic
preventing
intubation or
swallowing, and
resulting in
requires hydration or
documented
parenteral nutritional
aspiration
support
pneumonia
Scores= 0 to 3
Visual analog scale = 0 to 100, where 100 = worse condition
Painful
erythema,
edema, ulcers
but with ability
to swallow

[28, 50, 76]

[51, 77]
Score= 0
No lesions

Score= 1
Lesions
< 1cm2

Score= 2
Lesions 1-3 cm2

Score= 3
Lesions >3 cm2

N/A

World
Consortium for
Cancer Nursing
Research
(WCCNR)

Stage = 0
Lesions= 0
Normal
pink,
no edema,
no
infection

Stage = 1
Lesions =
1 to 4
Slight
redness,
mild edema,
no infections
but mild
discomfort

Stage = 2
Lesions > 4
(not coalescing)
Moderate redness,
edema, mild
xerostomia,
difficulty in eating
expect liquid or
bland foods

Stage = 3
Coalescing lesions,
total denudation of
oral cavity,
increased redness,
severe edema and
pain, marked
xerostomia, inability
to eat or drink
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Stages= 0 to 3

N/A
[50, 78]

Table 2-2: Use of non-therapeutic method as a prophylactic strategy in OM.

Generic
name

Trademark/
Brand name

Functional
properties

Laser therapy

Oral cryotherapy

-NA-

Cryotherapy

Lowintensity
laser therapy

Cheap,
readily
available
method

-NA-

Oral cooling
results in localized
vasoconstriction.

Laser therapy
enables
neovascularization
and brings forth
anti-inflammatory
response.

Level of success

Mode of action

• Contributes to
a decrease in
incidence and
severity of OM.

Cooling effect
results in a reduced
blood flow,
decreasing drug
distribution in
mucosal tissues
thereby greatly
reducing OM
incidence.
• Cyclooxygenase-2
(COX-2) inhibition.
• Upregulates
vascular
endothelial growth
factor (VEGF)
affecting
angiogenesis.

• Causes
discomfort in
patients.
• Reduces the
severity of oral
mucositis.
• Inhibits
inflammatory
response.

References

[79-81]
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Strategy

[82, 83]

Table 2-3: Use of topical analgesics as a prophylactic strategy in OM.

Benzydamine
hydrochloride

(Lidocaine
hydrochloride,
carbopol,
sodium
carboxymethyl
cellulose,
polyvinyl
-pyrrolidone,
mannitol was
used in
tablets)

Trademark/
Brand name

Tantum™

Functional
Level of success
Mode of action
properties
• Benzydamine
• Shows
• Inhibits
hydrochloride is a
prophylactic
inflammatory
non-steroidal
effect in
cytokines
drug.
radiotherapy
production.
(HNC, low doses).
• Produces
antiinflammatory and • But not effective • Effects in antitopical analgesic
in chemotherapy
inflammation.
effects.
induced OM.

• Licodaine acts as • Licodaine is
Altaseptic MM
an analgesic
effective in pain/ Xylocaine
similar to
relief, mostly
benzydamine in
when used in
Administration
function.
HSCT induced
• oral spray
OM.
• Provies local
• buccal
anaesthetic
tablets
effect.
• Overdose
through
possess a risk of
• Anionic polymers
mucoCNS toxicity (few
acts as a
adherence
were dizziness,
mucoadherent,
on inner lip
delirium, muscle
also sustains drug
twitching etc).
release.

References

[81, 84, 85]

• Provides a
localized
delivery
diffusing from
the tablet.
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Generic name

Lidocaine
spray/tablets
Buccal tablets / Oral spray

Topical analgesic

Oral mouth rinse

Strategy

[86, 87]
• Expected to
provide pain
relief with its
analgesic
effects.

Table 2-4: Use of various biology response modifiers as a prophylactic strategy in OM.
Generic name

TGF-β3

Biological response modifier

(Transforming
growth factor
β3)

KGF1
(keratinocyte
growth factor)
Also known as
fibroblast
growth factor
(FGF-7)

EGF
(Epidermal
growth factor)

Trademark/
Brand name

Functional properties

Intraepithelial
delivery

•

(Drug with
Chitosan gel
(Carrier)

•

Palifermin/
Kepivance™
systemic
delivery
Intravenous
administration
(first
approved
preventive
agent)
-NAEGF spray
providing
topical
delivery to
injured oral
mucosa

•

•

Level of success

• Early
administration
Chitosan functions a
improves wound
muco-adherent.
healing.
• Ineffective when
Gel carrier protects
administration
the therapeutic drug
was delayed (after
preventing rapid
3 or 5 days during
release.
cancer therapies).
KGF helps in wound • Reduces the need
for opioid
healing by its ability
analgesics in HSCT.
to mediate
reepthelialization.
• Such effects were
inconclusive
Utilizes
among OM from
mesenchymalchemo or
epithelial
radiation
interactions for
therapies.
tissue healing.

• Upregulates growth
rate of epithelial cell
and fibroblasts.
• Aids in cell renewal.

rhEGF (human
recombinant EGF)
showed therapeutic
effect on OM
induced from
chemo/
radiotherapy.

Mode of action

References

• TGF-β3 decreases oral
epithelial proliferation.
• Prevents tissue damage
from toxic effect of
cancer treatments.

• Downregulates proinflammatory cytokines.
• Stimulates
detoxification enzymes.
• Cytoprotective effect.
• Possess regenerative
effects enhances cellular
migration, proliferation
and differentiation.
• Possess cytoprotective
effect.
• Brings forth
homeostasis.
• Positively affects
angiogenesis.

[60, 88, 89]
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Strategy

[60, 90-93]

[94-96]

Table 2-5: Use of various oral mouth rinses as a treatment strategy in OM.
Generic name
Supersaturated
calcium
phosphate mouth
rinse.
(dibasic/
monobasic
sodium
phosphate,
sodium/calcium
chloride)
(No standard
formulation)
Maalox®,
milk of magnesia,
kaopectate,
antifungals,
topical steroids,
topic anesthetics
such as Benadryl®
or licodaine

Chlorhexidine
gluconate
mouthrinse

Brand
name

Caphosol®
artificial
saliva

Magic
mouth
wash

Oradex®

Functional properties

Level of success

• Significantly
• Inorganic phosphate
effective in BMT
plays a role in
patients.
regenerating damaged
mucosa.
• Effective against
hyposalivation and
• Calcium ions provide
xerostomia
anti-inflammation,
vasodilatation and
• Enables reduction in
coagulating effects
pain and disease
enabling tissue repair.
duration)
• Combination of
ingredients such as
antibiotic,
antihistamine,
antifungal, steroid,
local anesthetic or
antacid.
• Mixture of atleast
above 3 mentioned
ingredients.

Chlorhexidine is a
dicationic chlorophenyl
biguanide, which
possess excellent antibacterial properties.

• Ineffective, effects
were no different in
comparison to
ordinary saline
washes.
• Can result in
drowsiness and
numbness of oral
cavity including
tongue.

Effective in plaque
control.

Mode of action
• Moistens and
provides a
lubricative effect
on oral cavity.
• Intended to
restore pH and
normal ionic
balance in oral
cavity.
By utilizing the
individual
therapeutic effects
of formulation, it
was expected to
meet desired clinical
need (pain relief and
reduction in healing
time).
• Chlorhexidine
functions as a
bacteriostatic
agent (inhibits) at
low concentration.
• Bactericidal (kills)
at high
concentrations.

Reference

[64, 97100]
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Oral mouth rinse

Strategy

[4, 69, 93]

[101, 102]

Table 2-6: Use of Mucoadhesive gels as a treatment strategy in OM.

Mucoadhesive gels

Generic name
Polyvinyl
pyrrolidone
(PVP),
hyaluronic
acid (HA),
glycrrhetinic
acid (GA)
Acemannan
hydrogel™
(polymeric
acetylated
mannans
derived from
aloe vera
extracts)

Xylitol,
hyaluronan

Trademark/
Brand name

Gelclair®

RadiaCare™

Gengigel®

Functional properties
• PVP, HA are mucoadherents which
form protective
films.
• GA breaks down
active component
in flavoring agent.
Hydrogels derived
from aloe vera
possess growth
substance which
improves antiinflammatory and
wound healing activity
• Hyaluronan (HA) is a
key component in
extracellular matrix.
• HA helps in
migration,
proliferation and
differentiation of
keratinocytes.
• Xylitol functions by
slowing down
bacterial growth.

Level of success

Short-term pain
relief, temporary
improvement in
ability to eat or
drink

Mode of action
• Adheres to oral
mucosa forming a
protective barrier
over ulcerous
lesions.

• Not conclusive
(conflicting
results).
• Equivalent to
Gelclair® in its
mode of action.

• Provides temporary
pain relief through
tissue hydration
and from
lubricative effect
(Palliative therapy).

• Rapid pain relief,
although effects
are temporary.
• Weak
antibacterial
effect.
• Cannot be
recommended
for plague
control.

• Apart from barrier
effects, hyaluronan
in Gengigel® was
expected to provide
anti-inflammatory
effect.
• Enables reepithelization and
tissue regeneration.

References

[103-106]
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Strategies

[103, 107111]

[102, 112,
113]

Figure 2-1: Different grades of oral mucositis as per NCI assessment scales.
Adapted taken from feature article by Cawley, M.M. and L.M. Benson, Current trends in
managing oral mucositis, Clin J Oncol Nurs, 2005. 9(5): p. 584-92. [17]).
[(Photo courtesy: Mark Schubert, MSD), Reproduced with permission]
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Figure 2-2: Scheme showing pathogenesis of oral mucositis, potential treatment
strategies and treatment barriers associated with oral mucosal wounds. Treatment
strategies (protective barriers, therapeutic drugs) and its effects on treatment barriers
and OM pathogenesis were also shown.
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Figure 2-3: Scheme showing overall proposed application of LBL self- assemblies in oral
drug delivery.
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CHAPTER 3.

RESEARCH GOALS

3.1. Objective/Hypothesis
Multilayered affinity based polymeric systems can provide a durable protective
barrier over injured oral mucosa, offering a regenerative treatment strategy through
their resistive stability against the harsh intraoral environment.
3.1.1. Specific aim #1: Synthesize and characterize biotin functionalized polymers.
1. Synthesize biotinylated poly(acrylic acid) of different polymeric molecular
weights and extents of biotin conjugation.
2. Characterize product purity and degree of biotinylation using reverse-phase high
performance

liquid

chromatography

(RP-HPLC)

and

HABA

(4’-

hydroxyazobenzene-2-carboxylic acid) analysis [114].
3.1.2. Specific aim #2: Formulate LBL self-assemblies and evaluate in vitro chemical
stability.
1. Develop in vitro LBL assemblies from synthesized biotin functionalized polymers
and assess extent of self-assembly growth for different polymer molecular
properties.
2. Evaluate LBL chemical stability and barrier properties through in vitro tests in
physiologically relevant oral salivary and protease medium.
3. Estimate key factors that contribute to LBL development and LBL chemical
stability through exploratory statistical models and multivariate analysis.
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3.1.3. Specific aim #3: Evaluate LBL mechanical stability through ex vivo adhesion
studies.
1) Perform adhesion tests to demonstrate LBLs physical barrier effect in preventing
adhesion from surrounding tissues.
2) Evaluate LBLs mechanical stability (durability) through repeat contact barrier
tests to analyze their contact wear resistance.
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CHAPTER 4.

POLY(ACRYLIC ACID) BIOTINYLATION AND CHARACTERIZATION

In biochemistry, the process of conjugating biotin to proteins or macromolecules
is known as biotinylation. The biotinylated macromolecules in combination with protein
avidin / streptavidin has potential for a wide variety of applications utilizing the strong
non-covalent affinity between biotin-(strept)avidin linkages. Biotin-streptavidin
complexes form due to the combined effect of several hydrogen bonds and van der
Waals interactions which lead to a high association coefficient (Ka) in the order 1015 M-1
[115]. Such high affinity in biotin-streptavidin complexes is nearly 103-106 times greater
than antibody-ligand interactions [116]. The use of such characteristic biotinstreptavidin interactions in multilayered self-assembly enables a strong affinity and
specificity which are unaltered by environmental pH variation and ionic concentration.
Biotin-streptavidin interactions also possess a very high thermal stability [117]. Hence,
to develop such stable affinity based multilayered polymeric barriers; biotin
functionalization of polymer (biotinylation) represents an indispensable step. In this
study, poly(acrylic acid) (PAA), a weak polyanion with known anti-bacterial effects and
mucoadhesive properties is used in biotinylation synthesis [118, 119]. The adhesive
components in oral pathology (e.g., fibronectin and laminin) contain many positively
charged residues (e.g., arginine, lysine) [120, 121]. Hence, the addition of oppositely
charged polyanion PAA (negative polymeric backbone), is expected to improve polymer
binding capability due to electrostatic interactions.
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4.1. Materials and methods
4.1.1. Materials
Poly(acrylic acid sodium salt) (MW 10,000 and 50,000 Da) and PAA (MW 90,000
Da) were purchased from Polysciences, Inc. (Warrington, PA) and were lyophilized prior
to use. During lyophilization, PAAs in aqueous solution were frozen by mechanical
refrigeration and freeze dried to sublimate water. Polymer PAA was collected as dry
powdered mass. All other chemicals were used as purchased without any further
purification unless stated. Pentylamine-biotin and avidin were purchased from Thermo
Scientific (Rockford, IL). N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride
(EDC.HCl), 2-(N-morpholino)ethanesulfonic acid (MES) and 2-(4-hydroxyphenylazo)benzoic acid (HABA) were purchased from Sigma Aldrich (St.Louis, MO). Nhydroxysuccinimide (NHS) was purchased from Acros Organics (NJ).
4.1.2. Polymer biotinylation synthesis
PAA biotinylation was carried out with minor modifications to a previously
published procedure [122]. In polymeric biotinylation by EDC-NHS coupling chemistry,
the molar ratio of PAA: EDC: NHS (1:10:20) was fixed. The extent of biotin conjugation
on PAA was altered based on molar ratio of pentylamine-biotin to carboxylic acid repeat
unit in PAA. To obtain a low extent of biotin conjugation [Biotin+], a molar ratio of
pentylamine-biotin to PAA of 1:5 was used, whereas for a high extent of conjugation
[Biotin++] the molar ratio used was 1:2.5. All of the materials were weighed out to meet
the desired molar ratios. PAA, EDC and NHS were dissolved in 50 mM MES buffer and
transferred into a sealed flask at room temperature with a regulated pH of 5.0-6.0. To
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the reaction mixture, pentylamine-biotin was added immediately and the pH was
adjusted by either acid (HCl) or base addition (NaOH) to 7.0-8.0, in order to enhance the
reaction of carboxylic acid with amine to form a stable amide bond. The reaction was
carried out for a period of 24 hrs.
4.1.3. Purification and characterization
The biotinylation reaction mixture was filtered to remove any precipitate
suspensions (N-acylurea) formed during reaction. Further purification was carried out
using ultrafiltration (Millipore, USA), allowing for the removal of excess unreacted
pentylamine-biotin, EDC and NHS from the synthesized biotinylated PAA (Biotin-PAA)
product. RP-HPLC (Shimadzu Prominence) was carried out on ultrafiltered biotinylation
reaction samples. An isocratic mode with a mobile phase of acetonitrile (organic phase)
and water with 1% trifluoroacetic acid (aqueous phase) in (15:85) % volume ratio was
used in RP-HPLC analysis. All purified reaction samples were subjected to HABA-avidin
assay. HABA stock solution and HABA-avidin working solution was prepared as outlined
by Shuvaev et al.[114]. To the HABA-avidin working solution (red/orange colored),
purified reaction samples from polymer biotinylation synthesis was added. This addition
resulted in color change (pale orange/ yellow) which was measured from the decrease
in the absorbance at 500 nm using a UV-Vis spectrophotometer (Cary WinUV). By
comparing calibration made from known free biotin addition to HABA-avidin working
solution, the actual estimate of extent of biotinylation in different synthesized
biotinylated PAA molecules was determined.
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4.2. Results and discussion
4.2.1. Polymer biotinylation
PAA was functionalized with biotin through carbodiimide chemistry [123-126].
With an aim of developing LBL polymeric self-assemblies, biotin moieties were
incorporated into polymeric PAA chain. For biotin functionalization the most commonly
used reagents are N-hydroxysuccinimide (NHS) esters or N-hydroxysulfosuccinimide
(Sulfo-NHS) esters for carboxylic acid reaction with primary amines. 1-ethyl-3-[3dimethylaminopropyl]carbodiimide hydrochloride (EDC.HCl) is commonly used as a
zero-length aqueous phase cross linker in combination with NHS / Sulfo-NHS esters to
form a stable amide bond in biotinylated product. The proposed reaction scheme is
shown in Figure 4-1. During the biotinylation reaction, an O-acylisourea based
intermediate is expected to be formed by EDC activation on carboxylic acid (PAA). In the
absence of amino groups (pentylamine-biotin), this intermediate hydrolyzes to form
precipitate by-product N-acylurea [127, 128]. These intermediate were filtered off and
other excess components were removed from biotinylated product by ultrafiltration.
The presence of free unreacted pentylamine-biotin in reaction sample would
compete with biotinylated polymer product and thereby limits the use of 2-(4hydroxyphenylazo) benzoic acid (HABA) analysis in determining the extent of PAA
biotinylation. Hence reaction sample purification was carried out for an extended
duration until free pentylamine-biotin was completely removed (below negligible
limits). To detect the degree of the free pentylamine-biotin during and after reaction
sample purification, a reverse phase high performance liquid chromatography (RP-HPLC)
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analysis was carried out. From RP-HPLC analysis on all purified samples, complete
removal of free pentylamine-biotin (peak disappearance) was ensured; thereby its
product purity (> 99%) (see Figure 4-2). All post-purified reaction samples were
subjected to HABA analysis by addition to HABA-avidin complex. This addition replaces
the weakly bound HABA molecules (kd= 10-6 M) from HABA-avidin complex by a higher
affinity biotin molecules from biotinylated PAA (kd= 10-15 M) [129, 130], described in
scheme Figure 4-3. The release of free HABA results in a color change which was
quantified for synthesized reaction samples by the decrease in its absorbance at 500 nm
(see Figure 4-4). The extent of biotin conjugation to PAA chains was determined for
synthesized biotinylated PAAs of different polymer molecular weight (Figure 4-5). As
expected, biotinylated PAAs within same polymer MW (10,000/50,000/90,000) which
were synthesized from higher pentylamine-biotin to PAA molar ratio ([Biotin++]= 1:2.5)
contained an increased number of biotin molecules incorporated in polymer chain as
opposed to products prepared with a lower molar ratio ([Biotin+]= 1:5). Among
conjugated polymers, “[Biotin++]/PAA 90” possess the highest number of biotin
molecules per PAA chain (7.14 biotin molecules), whereas “[Biotin+]/PAA 50” and
“[Biotin+]/PAA 10” contained the least number of biotin molecules per PAA chain (1.2
biotin molecules).
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Figure 4-1: Synthesis scheme for poly(acrylic acid) biotinylation. Plot shows EDC-NHS
coupling chemistry by reaction of carboxylic acid from PAA and amine group from
pentylamine-biotin to form a stable amide bond in product biotinylated PAA (BiotinPAA).
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Figure 4-2: Reverse phase HPLC for detecting removal of unreacted biotin from reaction
sample. Plot shows free pentylamine-biotin peak (reference peak) and disappearance of
unreacted pentylamine-biotin on purification of biotinylation reaction samples
(polymer-biotin concentration ~0.12 mM).
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Figure 4-3: Scheme showing mechanism of HABA-avidin analysis which was used to
determine extent of biotinylation on ultrapurified reaction samples.
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Figure 4-4: UV-visible spectra of HABA-based assays for biotin. Extent of biotinylation is
determined through free HABA release where color change was detected by a decrease
in absorbance at 500 nm.
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Figure 4-5: HABA analysis results showing extent of polymer biotinylation.
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CHAPTER 5. CHEMICAL STABILITY TESTS ON LAYER-BY-LAYER SELF-ASSEMBLIES

The oral cavity is a complex environment containing bacteria, surfactants,
carbohydrate molecules (e.g. sialic acid) and wide variety of proteins or enzymes (e.g.
salivary peroxidase, lysozyme, α-amylase, carbonic anhydrase, fibronectin, secretory
Immunoglobulin A (sIgA), matrix metalloproteinases, kallikrein and lactoferrin) [131]. It
is possible that the effect of such diverse components could destabilize the LBL
assemblies yielding to proteolytic or salivary surfactant effects. Hence in evaluating such
possibility of premature barrier failure, an in vitro chemical stability study is performed
on LBL systems.
A bacterial protease enzyme “pronase” isolated from Streptomyces griseus is
used for studying LBL proteolytic stability. Pronase compositions typically contain
different exopeptidases and endopeptidases, which explains its non-specific proteolytic
activity[132]. An example of one such endopeptidase enzyme is serine protease, which
can hydrolytically break down peptide bonds on the carboxyl part of aspartic or glutamic
acid yielding non-specific protease behavior[133]. To evaluate the effects of oral saliva
on LBL assemblies, an unstimulated whole saliva (UWS) is used. Although salivary
medium possesses various components such as water, sugar, carbohydrates, inorganic
molecules, proteins and lipids, the effects of its rheological properties are mainly
derived from its salivary mucins. Mucins are glycoproteins which can influence salivary
viscosity and its spinnability (spinnbarkeit). UWS contains higher mucin level as opposed
stimulated whole saliva (generated during chewing) [134]. Hence, LBL barriers were
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studied under UWS to evaluate their possible de-assembling tendency in surfactant like
properties of UWS.
5.1. Materials and methods
5.1.1. Developing affinity based Layer by Layer (LBL) assemblies
Radiolabeling protein streptavidin: Protein streptavidin was radiolabeled (125IStreptavidin) and was used in studying LBL self-assembly development using a
radiotracing

method.

Iodogen®

iodination

reagent

(1,3,4,6-tetrachloro-3α-6α-

diphenylglycouril) (Thermo Scientific, Rockfort, IL) was dissolved in an organic solvent
chloroform and was added to a glass tube (2 mg/ml, 200 μl). The volatile chloroform
solvent was evaporated off from iodogen® reagent using dry nitrogen gas to form a thin
film covering the glass tube. Cold streptavidin (100 μl of 1mg/ml solution) was
introduced into the iodogen coated test tube, to which radioactive iodine (125I) was
added (~30 μCi) and incubated for at least 5 minutes to enable iodination of tyrosyl
groups of streptavidin [135]. The free iodine was removed from radiolabeled
streptavidin by spinning down in gel filtration columns (Biospin® 6 Tris columns).
Free iodine determination: The extent of free iodine content in the spin down product
(radiolabeled streptavidin) was estimated by the trichloroacetic acid (TCA) precipitation
method. TCA (20% (w/v), 1 ml) was added to protein mixture containing radiolabeled
streptavidin (2 μl of 1 mg/ml radiolabeled protein stock) and bovine serum albumin
(BSA) (1ml of 5% (w/v)). The TCA addition readily precipitates the protein mixture
(incubated for atleast 10 minutes) where the BSA presence aids in forming an
appreciable protein precipitate mass to separate radiolabeled proteins from free iodine
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by centrifugation. Pellets collected after centrifugation contained the precipitate from
radiolabeled streptavidin and cold BSA, whereas the supernatant solution was rich in
free iodine. By measuring radioactive gamma counts on supernatants and precipitates
separately, the extent of free iodine present was determined. All batches of
radiolabeled streptavidin used in the studies had minimal free iodine content (< 10%).
5.1.1.1. Base layer adsorption studies
To establish an initial base layer by which LBL can be formed, streptavidin
adsorption to radioimmunoassay (RIA) plates was performed. 100 µl of 125I-streptavidin
(1- 1000 nM) was added to the plates and was incubated for 1 minute, and then washed
at least 3 times with phosphate buffered saline (PBS). The amount of protein adsorbed
was measured using a gamma counter (Perkin Elmer).
5.1.1.2. In vitro LBL
In vitro LBL studies were carried out on RIA plates. Base streptavidin (Layer 1)
was formed on the RIA microplates on the basis of the base layer adsorption study data.
The vacant adsorption sites in the base layer were blocked using 5 wt% bovine serum
albumin (BSA) by providing an incubation time of at least 2 minutes. The unbound BSA
was removed by a series of PBS washes (at least 3 rinses). To the base streptavidin layer,
an alternating rinse of biotinylated PAA (2 minute incubation, 100 μl) and streptavidin
rinse (1 minute incubation, 100 μl) were provided. The molar ratio of biotinylated
polymer to streptavidin ratio was kept atleast 4 fold in excess to ensure all streptavidin
binding sites were occupied during LBL formation. The excess biotinylated polymer or
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streptavidin was removed by intermittent PBS rinses (atleast 3 times, 200 μl). To study
the LBL development, self-assemblies with different numbers of streptavidin layer in the
LBL system (NoL = 1, 3, 5, and 7) were characterized for various synthesized biotinylated
PAA materials.
5.1.2. Chemical stability tests on in vitro LBL assemblies
Chemical stability tests were carried out on the developed in vitro LBL systems.
Either unstimulated whole saliva (UWS) or protease enzyme pronase were used to study
LBL chemical stability. UWS was collected by the spitting method, with a harvesting lag
time of at least 2 hours from meal intake. Other variable salivary factors were kept
minimal by abstinence from smoking or drinking [136]. For proteolytic stability test,
pronase medium (0.01 % w/v) was used. Developed in vitro LBL systems were incubated
in oral salivary medium or in pronase medium for different times. Streptavidin mass
remaining in the LBL system after various incubation times was measured using gamma
counter.
5.1.3. Statistical analysis
Principal component regression (PCR) was performed using statistical software
(The Unscrambler® V9.7 and V10.1, Camo Software Inc) on the results of in vitro LBL
development and LBL chemical stability tests. The response variable, fractional increase
in radiolabeled streptavidin mass from the base layer “ML/M1” derived from in vitro LBL
tests was used in studying effects of LBL factors (MW, conjugation and NoL).
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Similarly response variables (t1/2 and mass loss at t1/2) derived from LBL chemical
stability analysis was used in studying effects of LBL factors (MW, conjugation and NoL).
Here, t1/2 is the time required for the LBL assemblies to degrade into halve their
maximum possible degradation (1/2*M∞). In PCR analysis, test of significance was
performed on regression coefficient ‘B’ (principal component slope), using uncertainty
tests.
Also, main effects of the factors affecting LBL chemical stability were studied
using various 3-way ANOVA models (Generalized Linear model (GLM) and 3-way nested
ANOVA) [137]. In analyzing in vitro LBL development a GLM model was used. Further
post-hoc analysis (multiple comparison methods) was performed using Bonferroni,
Sidak and Dunnett methods in the GLM model [138]. ANOVA plots containing main
effects and interactions plots were obtained for all response variables obtained from in
vitro LBL development and for LBL chemical stability studies. All 3-way ANOVA models
and post-hoc analysis were performed using statistical software (Minitab 16) [139]. For
all multivariate analysis (PCR), ANOVA tests and hypothesis testing performed, the
effects were considered significant only if P<0.05.
5.1.4. LBL degradation mechanism
To investigate the degradation mechanism, LBL systems with the same number
of self-assembly layers (NoL=5) were developed, using a modified in vitro LBL procedure.
For base layer degradation (Layer 1), the initial protein layer was applied using

125

I-

streptavidin with all subsequent layers using cold (non-radioactive) streptavidin. A
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similar procedure was adopted for studying degradation from the middle layer (Layer 3)
and outermost layer (Layer 5) by radiolabeling the specific individual protein layer.
Protein mass remaining in individual layers was measured for various salivary (UWS)
incubation times using a gamma counter.
5.2. Results and Discussion
5.2.1. Developing Layer-by-Layer self-assemblies
5.2.1.1. In vitro LBL assembly formation
For developing multilayered polymeric barriers, high affinity biotin-streptavidin
chemistry was used. PAA of different molecular weights (MW 10,000; 50,000; or 90,000
Da) with varying extent of biotin conjugation (Biotin+, Biotin++) were used for LBL
formation. A complete set of polymers used is listed in Figure 4-5.
In developing in vitro LBL assemblies on radioimmunoassay (RIA) plates an initial
base layer (Layer-1) of streptavidin was formed (see Figure 5-1). With higher
concentration of streptavidin addition during initial base layer formation studies, there
is a formation of a “high-density layer”, this is likely from a change in protein
conformation from side on position to end-on position. Such protein conformational
change on the surface could likely induce protein uncoiling or unfolding effects causing
denaturation or change in streptavidin active sites (binding pockets) for biotin
binding[140]. Hence, for in vitro LBL studies, protein coverage in the base layer was fixed
below monolayer saturation (189 nM), ensuring developed assemblies were from a
single base layer adsorbed to hydrophobic interface [141]. During LBL assembly,
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unoccupied sites in base layer were blocked using bovine serum albumin (BSA),
minimizing non-specific adsorption effects [142-144]. LBL systems with desired number
of streptavidin layers were developed over this protein base layer according to the
scheme shown in Figure 5-2.
The extent of LBL development was analyzed from the fractional increase in
radiolabeled streptavidin mass from the base layer, “ML /M1”. The results show that
significantly more material was deposited during LBL assembly growth using high MW
biotinylated polymers (Biotin-5.55/PAA 90, Biotin-7.14/PAA 90) (see Figure 5-3). The 7layered assemblies prepared using biotinylated polymers (Biotin-PAA 90) possessed
nearly 2.6 fold (161-197 %) higher streptavidin mass than the unconjugated polymer
(Biotin-0/PAA90) assemblies, indicating the successful formation of a multilayered
assembly as a result of the affinity linkages. Interestingly, the high MW unconjugated
polymer (Biotin-0/PAA 90) could form an additional protein layer with its weak charge
based interactions, yet were unable to form multilayer structures. Low MW polymers
(PAA 10), irrespective of their extent of biotinylation, were unable to form LBL
assemblies (Figure 5-5). This poor self-assembly formation was due to the polymer’s
tendency to destabilize the adsorbed protein base layer, most likely due to PAA’s
surfactant like effects [145] (Figure 5-5). LBLs developed using mid-range MW (50,000
Da) biotinylated polymers (Biotin-1.23/PAA 50, Biotin-2.75/PAA 50) possessed moderate
LBL assembly formation tendency, as expected (Figure 5-4). Self-assembled layers of
Biotin-PAA 50 materials were not as substantial as those formed with high MW
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polymers (PAA 90), but were better than low MW polymers (PAA 10). This study of
molecular weight shows that higher MW enhances the formation of LBL assemblies.
Traditional LBLs formed from polyelectrolyte multilayers (PEM) exhibit
exponential (non-linear) layer growth whether the layers are formed using only
polypeptides or with biological components [146-148]. Hence, it was hypothesized that
the weak non-linear increase in biotin content found in unconjugated high MW
polymers (Biotin-0/PAA 90) was likely a result of weak polyanion (PAA) interactions with
the protein (streptavidin). PEMs of highly charged polymers typically result in linear
growth[146]; it is likely that the nearly linear assembly trend found in LBLs of high MW
polyanion PAA (Biotin-5.55/PAA 90 and Biotin-7.14/PAA 90) is due to the significant
contributions from stable affinity based biotin-streptavidin linkages.
5.2.1.2. Multivariate analysis on in vitro LBL assemblies
Principal component regression (PCR) on in vitro LBL was performed to analyze
its possible multifactorial dependence and thereby ascertain significant LBL factors that
contribute to self-assembled layer growth. The possible LBL factors that influence
response variable (ML/M1) were polymer MW, extent of biotin conjugation and number
of layers (NoL). The results of PCR analysis demonstrated significant main effects from
all LBL factors with its interactions (see Table 5-1). The significant main effect
substantiates that all LBL factors contribute to self-assembly growth by affecting
response variable. From interactions, a significant resultant positive influence caused by
interdependence of various LBL factors in affecting assembly growth was observed. The
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contribution of interactions was shown through various significant 2-way interactions
(MW*Conj, Conj*NoL and MW*NoL) and squared interactions (Conj*Conj and
MW*MW). This demonstrates the effect of LBL assembly growth was a result of
contribution from all LBL factors with its combined main effects and a synergistic role of
factor interactions. The results of PCR analysis was compared with analysis from
generalized linear model (3-way ANOVA) for its main effects. The main effects were
found to be consistent in both the analysis thereby verifies the significant main effect
contributions from various LBL factors, shown in Table 5-2.
ANOVA plots studying main effect trends in LBL factors showed better assembly
formation from increasing polymeric MW (Figure 5-6). The main effects showing higher
protein mass in assemblies with increasing layers (NoL) reinstates the assembly growth
observed from earlier experimental results. The effect of conjugation in distinguishing
from unconjugated materials (Biotin-0) was evident at relatively higher biotin
conjugations (Biotin- 5.55/7.14). LBL factor interactions, which were found significant
through earlier conducted multivariate analysis (PCR model), were analyzed for their
trends using two way interactions plot in ANOVA (Figure 5-7). A more substantial
interaction was evident in systems of LBLs containing higher polymeric MW, better
conjugation and with increased assembly layers. Thus, greater interdependence
between various LBL factors contributed to enhanced assembly growth.
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5.2.2. LBL chemical stability
LBL systems developed for various synthesized Biotin-PAA materials (of different
MW/conjugation/NoL) were subjected to in vitro chemical stability tests. With an aim of
studying intra oral chemical effects, LBL assemblies were subjected to stability under
bacterial protease and unstimulated whole saliva (UWS). The effect of bacterial
protease (pronase) is likely to offer more significant impact on LBL destabilization with
its strong proteolytic effects. Such proteases, however, may exhibit minimal surfactant
like effects. In contrast, UWS is likely to possess weak proteolytic effect although its
surfactant like properties could dominate de-assembling of LBL barriers.
5.2.2.1. LBL protease stability
In LBL stability under proteolytic pronase, the unconjugated polymers (Biotin0/PAA 90, Biotin-0/PAA 10) were readily degraded, resulting in poor chemical stability
(Figure 5-8 and 5-11). The stability of Biotin-0/PAA 90 material was found to be
indistinguishable from the streptavidin base layer (Layer 1) further demonstrating the
weak association offered by unconjugated polymers (see Appendix figure A.4.1.). In
biotin conjugated polymers (Biotin-5.55/PAA 90 and Biotin-7.14/PAA 90), aided by their
affinity-based linkages, improved LBL stability was noticed (Figure 5-8). In studying layer
effects, LBLs (Biotin-5.55/PAA 90, Biotin-7.14/PAA 90) with increased number of layers
(NoL) yielded better assembly stability (Figure 5-9). This improved stability from higher
number of assembled layers was a result of better barrier effects from its multilayered
polymeric structures. In LBLs of high MW polymer (PAA 90) distinctively better barrier
stability was observed as when compared to lower MW polymer (PAA 10), thereby
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emphasizing the important role played by polymer MW in affecting LBL stability (Figure
5-10). Stability of low MW polymers (Biotin-1.21/PAA 10, Biotin-4.91/PAA 10) was
comparable to the streptavidin base layer (Layer 1). This weak barrier stability from PAA
10 materials is likely a result of their shorter polymeric chains which contributed to poor
LBL formation and enhanced surfactant like effects, resulting in an enhanced
streptavidin detachment from LBL assemblies (Figure 5-11). Also, protease stability
studies in LBLs of midrange MW (50,000 Da) were performed, and stability results of LBL
factor effects are listed in Appendix section A-5 and A-6.
5.2.2.2. Multivariate analysis on LBL protease stability
Multivariate analysis (PCR) was performed on protease stability response using
“mass loss at t1/2” as an indicator of extent of LBL degradation. It was observed that all
LBL factors (MW, conjugation and NoL) showed significant contributing effects on
degradation rate. Interestingly, with absence of any factor interactions all the effects
resulted from direct influence of each factor on extent of LBL degradation, emphasizing
an additive/non-synergistic dependence on stability (see Table 5-3). In studying factors
controlling rate of LBL degradation (t1/2), an important role played by polymer MW and
number of assembly layers (NoL) was observed with their significant main effect
contributions. The role of conjugation and effects of factors interdependence
(Interactions) were found insignificant to affect LBL degradation rate, thereby
demonstrates its weak influence.
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5.2.2.3. LBL salivary stability
Unstimulated whole saliva (UWS) with little to no protease was not expected to
significantly degrade streptavidin layers from assemblies. Indeed, detached protein (1930%) observed in LBLs of PAA 90 materials were likely from surfactant effects of saliva.
In LBLs under UWS, biotin conjugation did not seem to be a strong effecter on
barrier stability (Figure 5-12). However, layer effects were significant where by
increasing LBL layers the protein loss from assemblies was suppressed (Figure 5-13).
This layer effect was important as with increased network density from increased
layered assemblies is expected to form resilient barrier against surfactant qualities of
saliva. Polymer molecular weight effects in UWS were similar to protease studies where
higher molecular polymers resulted in better stability substantiating the role of polymer
MW in LBL stability (Figure 5-14). Interestingly, PAA 10 materials resulted in enhanced
protein loss from assemblies as observed in protease studies, reasserting earlier
described inherent surfactant effects of low MW PAA (Figure 5-15).
5.2.2.4. Multivariate analysis on LBL salivary stability
Principal component regression (PCR) on salivary stability studying important
factor effects of LBL responses (mass loss at t1/2 and t1/2) demonstrated significant
contributions from main effects of polymeric MW and number of assembly layers (NoL)
(Table 5-4). Unsurprisingly, the main effects of conjugation were found to be
insignificant for all LBL response variables. This substantiates the earlier observed weak
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conjugation effects. With absence of interactions for all LBL factors, the absence of
factor interdependence was reinstated as was suggested for LBL protease stability.
5.2.3. Statistical analysis on LBL chemical stability
The significance of LBL factors (main effects) with chemical stability response
variables were determined using 3-way ANOVA models (see Figure 5-16) and compared
with earlier conducted PCR analysis. With absence of factor interactions as determined
in PCR analysis, the effects of LBL factors on stability response were captured by the
factor main effects. The results of PCR analysis were in agreement with the analysis
carried out using 3-way ANOVA model (3-way nested ANOVA) thereby confirming the
significant effect of MW and NoL on LBL chemical barrier stability, shown in Table 5-5.
From post-hoc analysis (Bonferroni, Sidak and Dunnet methods) conducted on LBL
factors in generalized linear model (GLM), LBL assemblies from biotinylated PAA’s of
higher MW (90,000 Da) and high NoL (7), consistently resulted in a stable chemical
barriers (see Table 5-6).
5.2.4. LBL degradation mechanism
LBL degradation mechanism under oral chemical effects can occur by either topto-down delamination or fissure mode or base layer delamination (see Figure 5-17). In
top-to-down delamination mechanism, the outer layer of LBLs will be more prone to
chemical effect, followed by gradual delamination from outer to inner layers. In this
mode, innermost layers are expected to be least susceptible. Under fissure mode, the
kinetic rate loss from inner, middle or outer layers in LBLs should be indistinguishable
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(uniform) resulting in a porous LBL network on chemical degradation. Other possible
degradation mode involves base layer delamination, which through its susceptible inner
layer under oral chemical effects can destabilize the LBL assemblies resulting in a
sudden rapid loss.
In determining the mechanism through which LBL degradation occurs, 5-Layered
assemblies was developed using high MW polymers (PAA 90). LBLs with individual
radiolabeled streptavidin layers (innermost or middle or outermost), scheme shown in
Figure 5-18, were subjected to salivary degradation.
Each individual layer in LBLs of biotinylated polymer (Biotin-7.1/PAA 90)
performed better than its respective layer from unconjugated polymer (Biotin-0/PAA 90) (Figure 5-19). This notable increase in stability reinforces the role of multi-layered
structures in providing chemical barrier effects as described earlier. The rapid innermost
layer loss from unconjugated materials verifies their inability to develop LBL assemblies.
The assemblies of biotinylated polymers followed a top to bottom progression
mechanism in chemical degradation suggesting a surface erosion mechanism and an
operative polymeric barrier effects from multilayered structures. In LBL systems of
biotinylated PAA material (Biotin- 7.1/PAA 90), the outermost layer (Layer 5) was found
to be most susceptible to proteolytic degradation. A higher protein loss from outer layer
was due to the direct salivary effects in absence of any capping polymeric layer to
provide barrier effect. The innermost layer (Layer 1/Base layer) with its overlaid
polymeric layers provides an effective barrier effect indicated by its reduced protein loss
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from assemblies (Figure 5-19). As expected, the middle layer (Layer 3) possessed better
stability when compared to outer layer, but resulted in more protein loss in comparison
to innermost layers. This barrier tendency exhibited by slow degradation effects of
middle and innermost layer was absent in unconjugated materials (Biotin– 0/PAA 90).
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Table 5-1: Table shows summarized results of PCR analysis on in vitro LBL assembly
development, where interactions (2-way and squared interactions) were found to be
significant. All LBL factors like MW, conjugation and NoL showed significant main effects
for response variable (ML/M1). Table contains ‘P’ values obtained from test of
significance on regression coefficient (B) where“” represents statistically significant
factors. Specific factors were considered significant only if P < 0.05. (see Appendix
Figure A-2, for output results obtained during analysis)

p-values
for Beta
Coefficient
Response
variable
(LBL
growth)
ML/M1

LBL factor effects
Main effects

2-way Interactions

Squared Interactions

Conj

NoL

MW*
Conj

MW*
NoL

Conj*
NoL

MW*
MW

Conj*
Conj

 













0

0

M
W
0

0

0.0001 0.0001
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0.026

NoL*
NoL

0.0001 0.0001

Table 5-2: Summarized results from 3-way ANOVA model (Generalized Linear Model) on
main effects of in vitro LBL assembly development. Table contains ‘P’ values obtained
from test of significance on regression coefficient (B) where“” represents statistically
significant factors. Specific factors were considered significant only if P < 0.05.

LBL factors – Main effects
Response variable
MW

Conjugation

NoL







0

0

0.001

ML/M1
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Table 5-3: Summarized results of principal component regression (PCR) analysis on LBL
protease stability response variables (mass loss at t1/2 and t1/2) to study effects of
various LBL factors (MW, conjugation and NoL). Results were obtained by conducting
test of significance (uncertainty tests) on regression coefficient (Slope “B”) derived from
principal component analysis. From results, interactions were found to be insignificant
whereas factors like MW, NoL showed significant main effects for LBL response
variables. Also role of conjugation in affecting mass loss from assemblies were found
significant. Table contains ‘P’ values obtained from test of significance on regression
coefficient (B) where“” represents statistically significant factors. Specific factors were
considered significant only if P < 0.05. (see Appendix figure A-7, for output results
obtained during analysis).

p-values
for Beta
Coefficients
Response
variables
(LBL
protease
stability)
Mass loss
at t1/2
t1/2

LBL factor effects

Main effects

2-way Interactions

MW

Conj

NoL







0

0

0.0174


0

Squared
Interactions

MW*
Conj

MW*
NoL

Conj*
NoL

Conj*
Conj

NoL*
NoL

0.3063

1

1

0.9775

1

0.8771

1

1

0.9997

1


0.5778

0.0546
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Table 5-4: Summarized results of principal component regression (PCR) analysis on LBL
salivary stability response variables (mass loss at t1/2 and t1/2) to study effects of various
LBL factors (MW, conjugation and NoL). Results were obtained by conducting test of
significance (uncertainty tests) on regression coefficient (Slope “B”) derived from
principal component analysis. From results, interactions were found to be insignificant
whereas factors like MW, NoL showed significant main effects for LBL response
variables. Table contains ‘P’ values obtained from test of significance on regression
coefficient (B) where“” represents statistically significant factors. Specific factors were
considered significant only if P < 0.05. (see Appendix figure A-10, for output results
obtained during analysis)

p-values
for Beta
Coefficients
Response
variables
Main effects
(LBL
salivary
MW
Conj
NoL
stability)
Mass loss
at t1/2
t1/2


0

2-way Interactions

Squared
Interactions

MW*
Conj

MW*
NoL

Conj*
NoL

Conj*
Conj

NoL*
NoL

0.7611

1

1

0.9993

1

0.8392

1

1

0.9996

1


0.1392


0

LBL factor effects

0.0092


0.4303

0.0083
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Table 5-5: Summarized results from 3-way nested ANOVA model on LBL chemical
stability. Specific factors were considered significant for P < 0.05. Design of nested
ANOVA model was illustrated in Figure 5-16.

LBL factors
Proteolytic medium

Response variable
MW

Conjugation

NoL





0.001

0

Mass loss % for t1/2
0.122
Pronase





t1/2
0.001

0.581



0.006



Mass loss % for t1/2
0.005

0.133

0.001

Saliva





t1/2
0
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0.949

0.011

Table 5-6: Summary of results from 3-way ANOVA models and from post-hoc analysis. Table shows specific significant factors
contributing to LBL chemical stability. Specific factors were considered significant for P < 0.05. A 3-way ANOVA (Generalized
linear model (GLM)) was performed and on performing post-hoc tests (using Bonferroni, Sidak and Dunnett), the following
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results were obtained.

Figure 5-1: Extent of base layer coverage - streptavidin adsorption on base layer. Plot
shows protein

adsorption

for

various incubated

streptavidin concentration,

characterizing extent of protein coverage on base layer (Layer 1) available for LBL
assembly growth.

60

Figure 5-2: Scheme showing LBL assembly development using biotin-streptavidin affinity
linkages by alternate additions of protein streptavidin and synthesized biotinylated PAA.
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Figure 5-3: In vitro LBL assembly formation using high MW (90,000 Da) PAA of various
extent of biotin conjugation.
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Figure 5-4: In vitro LBL assembly formation using mid-range MW (50,000 Da) PAA of
various extent of biotin conjugation.
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Figure 5-5: In vitro LBL assembly formation using low MW (10,000 Da) PAA of various
extent of biotin conjugation.
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Figure 5-6: Main effects plot from ANOVA studying LBL factor effects on development of
in vitro LBL assemblies.
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Figure 5-7: Interactions plot from ANOVA studying LBL factor effects on development of
in vitro LBL assemblies.
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Figure 5-8: Effect of factor “extent of biotin conjugation” in LBL protease stability. Plot
shows biotin conjugation effect by analyzing self-assemblies developed from polymer
PAA of same MW (90,000 Da) with equal number of assembly layers (NoL=7) and
through comparison with different extent of biotin conjugation. Similar analysis can be
performed for same PAA 90 materials with different NoL in assemblies such as NoL=3
(see Appendix figure A-3.1), NoL=5 (see Appendix figure A-3.2). Also conjugation
effects on mid-range MW (50,000 Da) polymeric materials (see Appendix figure A-5.1,
A-5.2, and A-5.3) and in low MW (10,000 Da) polymeric materials (results not shown)
was analyzed.
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Figure 5-9: Effect of factor “number of assembly layers (NoL)” in LBL protease stability.
Plot shows layer effect in self-assemblies developed from high MW (90,000 Da)
biotinylated PAA (Biotin-7.1 / PAA 90). Similar analysis was performed for the same PAA
90 materials with different conjugations such as Biotin=0 (see Appendix figure A-4.1),
Biotin=5.55 (see Appendix figure A-4.2). Also layer effects on midrange MW (50,000 Da)
polymeric materials (see Appendix figure A-6.1, A-6.2 and A-6.3) and in low MW
(10,000 Da) polymeric materials ((results not shown) was analyzed.
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Figure 5-10: Effect of factor “polymer MW” in LBL protease stability. Plot shows MW
effect by analyzing self-assemblies developed of equal number of assembly layers
(NoL=7) and providing comparison with different MW (90,000/10,000 Da) PAA
materials. Similar analysis can be performed with different number of LBL layers such as
NoL=3 and NoL=5 (results not shown).
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Figure 5-11: Streptavidin mass loss (%) at M∞ in LBL protease stability. Plot shows
streptavidin mass loss (%) at M∞ obtained from protease stability plots of different LBL
systems (MW / biotin conjugation / NoL). For similar analysis on midrange MW (50,000
Da) polymeric materials see Appendix figure A-6.4.
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Figure 5-12: Effect on factor “extent of biotin conjugation” in LBL salivary stability. Plot
shows biotin conjugation effect by analyzing self-assemblies developed from polymer
PAA of same MW (90,000 Da) with equal number of assembly layers (NoL=7) and
providing comparison with different extent of biotin conjugation. Similar analysis can be
performed for same PAA 90 materials with NoL=3 (see Appendix figure A-8.1), NoL=5
(see Appendix figure A-8.2). Also conjugation effects on low MW (10,000 Da) polymeric
materials was analyzed (results not shown).
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Figure 5-13: Effect on factor “number of assembly layers (NoL)” in LBL salivary stability.
Plot shows layer effect from LBL stability tests in self-assemblies developed from high
MW (90,000 Da) biotinylated PAA (Biotin-7.1 / PAA 90). Similar analysis was performed
for the same PAA 90 materials with different conjugations such as Biotin=0 (see
Appendix figure A-9.1), Biotin=5.55 (see Appendix figure A-9.2). Also layer effects on
low MW (10,000 Da) polymeric materials was analyzed (results not shown).
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Figure 5-14: Effect on factor “polymer MW” in LBL salivary stability. Plot shows MW
effect by analyzing self-assemblies developed of equal number of assembly layers
(NoL=7) and providing comparison with different MW (90,000/10,000 Da) PAA
materials. Similar analysis can be performed with different number of LBL layers.

73

Figure 5-15: Streptavidin mass loss (%) at M∞ in LBL salivary stability. Plot shows
streptavidin mass loss (%) at M∞ obtained from salivary stability plots of different LBL
systems (MW / biotin conjugation / NoL).
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Figure 5-16: Scheme showing design used in 3-way nested ANOVA analysis which
contains group (MW= 90,000 and 10,000), with subgroups (Biotin conjugation) and
(NoL).
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FISSURE MODE

Figure 5-17: Possible LBL degradation mechanism under oral chemical effects.

BASE LAYER DELAMINATION
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TOP-TO-DOWN DELAMINATION
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Figure 5-18: Scheme shows developed 5-layered LBL systems, to study degradation mechanism from innermost, middle and
outermost layers by radiolabeling respective layers in self-assemblies 1, 3 and 5.

Biotinylated polymer (Biotin- 7.1 / PAA 90)
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Unconjugated polymer (Biotin- 0 / PAA 90)

Figure 5-19: Results studying mechanism of in vitro LBL degradation. 5-layered assemblies were developed from high MW
(90,000 Da) biotinylated PAA (Biotin-7.1 / PAA 90) and compared with unconjugated PAA (Biotin-0 / PAA 90) using mass loss
(%) from individual radiolabeled layers.

CHAPTER 6. MECHANICAL STABILITY TESTS ON LAYER-BY-LAYER SELF-ASSEMBLIES

As a result of mandibular motions and abrasion from food, the oral mucosa is
continually exposed to wear conditions. In an oral environment, it is expected that shear
and abrasion forces are the main factors that influence LBL barrier destabilization.
Hence, in testing LBLs barrier durability and wear resistance against intraoral abrasions,
repeat contact barrier fatigue test were performed on ex vivo LBLs. Such adhesion
testing is expected to be representative of in vivo conditions and provide a measure of
LBLs performance in an intraoral mechanical environment. In evaluating LBLs
mechanical stability, porcine skin patches were chosen as a model tissue substrate due
to their structurally similar collagen arrangement to a human dermis [149, 150].
6.1. Materials and methods
6.1.1. Ex vivo LBL
Ex vivo LBL studies were developed on pig skin tissue. Porcine skin patches of
dimension (5 mm x 5 mm) were used. Assembly development over tissue-protein base
layer was carried out by alternating polymer/protein rinses, adopting the same
procedure as described earlier for in vitro LBL studies. For ex vivo LBL studies,
biotinylated PAA of MW 50,000 Da was used.
6.1.2. Mechanical stability tests on ex vivo LBL assemblies
Mechanical stability was studied on ex vivo LBL assemblies using a mechanical
fatigue tester, Bose Electroforce (ELF 3300 test system) equipped with a 1 kg load cell.
Porcine skin patches (16 mm diameter) were thawed to room temperature and rinsed
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with PBS to avoid tissue dryness, emulating oral wounds. Tissues with dermal surfaces
facing each other were mounted to loading platens using cyanoacrylate and fixed in
place by applying a constant load.
In the adhesion tests, a compressive load of 3 N (305.8 g) was applied with a
ramp rate of 10 g/sec under load control and was stabilized at the load for 1 minute.
Under displacement control, pull off was conducted at a rate of 0.1 mm/sec until full
tissue separation occurs. Adhesion tests were performed on tissues before (tissue trend)
and after LBL development (LBL trend). LBL assembly was developed on tissue fixed to
the lower platen using the same procedure as described earlier in ex vivo LBL studies,
using cold streptavidin (non-radioactive) for the studies. In LBL fatigue resistance tests,
contact loadings of 20-25 cycles (load–pull offs) were provided after LBL growth. During
wear tests, tissue dryness was avoided by constant wetting with PBS between the cycles
thereby maintain similar tissue working conditions. By maintaining constant tissue
wetting conditions, the variation caused by tissue dryness between loading cycles were
minimized. Tissue trend was obtained prior to assembly development to ensure that
variations in tissues on loadings were not significant. Contact loadings of a minimum of
10 cycles were performed to determine this trend.
6.2. Results and Discussion
6.2.1. Ex vivo LBL
In order to determine the ability to develop LBLs on tissue and to validate future
ex vivo LBL tests, tissue assembly development using PAAs of MW 50,000 Da (PAA50)
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was studied. Porcine skin patches of equal dimensions were used during studies,
thereby maintaining a consistent surface area. Here, LBL assemblies were developed
over tissue-protein base layer; utilizing the non-specific protein interactions with tissue
surface receptor sites to form tissue-protein complex in base layer [151, 152]. From ex
vivo LBL studies, biotinylated polymers (Biotin- 2.75 / PAA 50 and Biotin- 1.23 / PAA 90)
showed a significantly better self-assembly ability with higher assembly layers (NoL= 4 &
5) as when compared to unconjugated polymer (Biotin-0 / PAA 90) (Figure 6-1). In 5layered LBL assemblies (NoL=5) for biotinylated PAA materials (Biotin-1.23/PAA 50,
Biotin-2.75/PAA 50), the streptavidin mass per tissue surface area was 3.18 mg/m2 and
3.62 mg/m2, respectively, which was 31-49 % greater adsorbed protein mass compared
to the unconjugated PAA material (Biotin-0/PAA 50). For unconjugated polymer (Biotin0/PAA 50) there was a relatively weak streptavidin mass increase suggesting a nonspecific binding during assembly growth verified through control comparison with
extent of protein adsorption in tissue without any polymer addition during assembly
growth. From ex vivo studies, the ability to form and thereby to distinguish tissue-LBL
assemblies even with relatively low assembly layers (NoL=5) from conjugated polymers
was deduced.
6.2.2. LBL mechanical stability
In studying LBL durability and its wear resistance, adhesion tests were
performed on developed ex vivo LBL assemblies, scheme shown in Figure 6-2. For
developing ex vivo assemblies of better stability during mechanical tests, the key
parameters as determined from earlier chemical stability studies and multivariate
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analyses were utilized. The earlier results deduced LBLs of conjugated materials with
increased NoL and higher MW contributed to better LBL stability. Hence during
adhesion tests, ex vivo LBLs of relatively high polymeric MW (50,000 / 90,000 Da) and
increased assembly layers (NoL=14) were developed for different extent of biotin
conjugation.
Adhesion tests were studied through rendered physical barrier effects of
multilayered polymeric assemblies. This barrier effect from ex vivo LBL was measured
through its extent of adhesive suppression in surrounding tissue (tissue mounted on
upper platen). In analyzing LBL barrier durability, a repeat contact barrier fatigue model
was used, where the developed ex vivo assemblies was subjected to repeated
mechanical loading cycles (load-pull offs).
During adhesion tests, for each load-pull off cycle, a work of separation (WoS)
was found through area under the curve in load vs. displacement plots, shown in inset
Figure 6-3. On providing repeated loading cycles on tissues prior to assembly
development, a “tissue trend” was obtained which accounts for possible tissue
variations on repeated loadings. On developing ex vivo LBL over this studied tissue,
repeated contact loading was provided to give a “tissue LBL trend” which evaluates LBLs
wear resistance, shown in Figure 6-3.
From adhesion test results, biotinylated LBLs (Biotin- 7.1 / PAA 90 & Biotin- 2.75/
PAA 50) were able to significantly reduce tissue surface adhesion by its barrier property
reflected from its decreased peak area, as shown in Figure 6-4. In analyses from wear
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tests, these biotinylated polymers were able to maintain their physical barrier effect by
remaining non-adhesive to surrounding tissues, even after numerous contact loadings.
This physical barrier effect from biotinylated materials (Biotin- 7.1 / PAA 90 & Biotin2.75/ PAA 90) is shown in Figure 6-4, by its decreased work of separation (WoS) and
with its minimal increase of WoS on providing repeated loading cycles (expressed in
terms of tissue normalized WoS). A control from LBL of unconjugated high MW (90,000
Da) polymer (Biotin-0/PAA 90) resulted in poor barrier stability with an increased
polymer adhesion to surrounding tissues. This enhanced adhesion in unconjugated
polymers was likely a result of protein/polymer charge based interactions on
surrounding tissue caused by its weakly formed layers. With LBLs of increased biotin
conjugation better physical barrier was formed (Biotin-7.1 > Biotin-2.71 > Biotin-0)
thereby demonstrates the effect of biotin conjugation in formulating durable barriers.
Thus biotinylated polymers of higher MW and NoL yielded better barrier stability.
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Figure 6-1: Ex vivo tissue LBL assembly formation. Plot shows LBL assembly formation
from PAA of MW (50,000 Da) with biotin conjugation ([Biotin++] =2.75 and [Biotin+]
=1.23).
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Figure 6-2: Scheme for ex vivo LBL adhesion testing. Developed tissue-LBL assemblies
(lower platen) were subjected to adhesion loading through load-pull off cycles.
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Figure 6-3: Repeated contact barrier fatigue tests. By providing repeated contacts of
loading cycles (load-pull offs), adhesion trends were studied before and after LBL
development, thereby studying LBL wear resistance. Plots show significant wear
resistance from LBL barriers developed from biotinylated PAA (Biotin- 7.1/PAA 90/14
Layers) with reduced work of separation (WoS) on repeated LBL loading cycles. Inset
plot shows load vs. displacement curves collected during adhesion tests before and after
LBL development using biotinylated PAA (Biotin-7.1/PAA 90/14 Layers). Decrease in
adhesion was shown by reduced WoS (area under the curve).
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Figure 6-4: Summary of results from mechanical testing. 14 layered LBL assemblies developed from various PAA material
(unconjugated (Biotin-0/PAA 90), (Biotin 2.75/PAA 50) and (Biotin 7.1/PAA 90)) were subjected to repeated loading cycles.
The extent of adhesion on repeated contact was shown by tissue normalized work of separation (WoS / % tissue control). A
hypothesis test using paired t-test was carried out on all LBL loadings trend and was found significant with P < 0.01.

CHAPTER 7. CONCLUSION AND FUTURE STUDIES

In this research, the ability to develop affinity based multilayered polymeric selfassembled multilayers was demonstrated. From chemical stability results and through
explorative multivariate analysis, relationship between polymer properties and barrier
function were obtained. LBLs of biotinylated polymers with higher MW and increased
number of assembly layers demonstrated improved barrier properties. By evaluating
LBL mechanical stability using a barrier fatigue model it was found LBLs of biotinylated
polymers resulted in a durable barrier with excellent wear resistance. Thus, the affinity
based multi-layered polymeric assemblies with their stable barrier property offer a
potential regenerative treatment strategy for oral wounds.
With promising LBL stability results, the future study will be directed towards
integrating therapeutic function to these stable multilayered assemblies. Potential
future work involve drug loading studies analyzing the capping effects of overlaying
polymer network and optimizing the zone of drug loading within assemblies studying
their drug release kinetics. With current better understanding in pathogenesis of OM, it
was well documented in the literature [39], the active role played by reactive oxygen
species (ROS) in disease initation. Hence, it was hypothesized LBL assemblies with their
incorporated antioxidant nanoparticles (drug loadings) can formulate into an effective
drug delivery system. Thus with this proposed treatment strategy a better tunable
barriers which contribute to drug protection and thereby modulate drug release kinetics
can be achieved.
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APPENDIX
A.1. Base layer protein adsorption kinetics
Method: Radiolabeled streptavidin (541 nM) under un-agitated conditions was held for
different incubation time in RIA plates and protein bound to the plates were measured
after removing the unbound streptavidin using repeated PBS rinses (atleast 3).
Discussion: Under static conditions, monolayer coverage was obtained by providing an
incubation time of 1 hour. Protein mass that resulted in monolayer coverage and its
kinetics was obtained through this study. As expected, the mass of streptavidin required
to form monolayer was consistent with the earlier conducted base layer protein
adsorption studies, a result due to same surface area availability for protein adsorption.

Figure A-1:

Base layer adsorption kinetics - Plot shows kinetics of base layer

streptavidin adsorption for various incubation times in RIA plates
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A.2. Multivariate analysis on in vitro LBL assembly development (uncertainty plots)

Figure A-2: Principal component regression analysis on in vitro LBL response variable
(ML/M1) to study effects of various LBL factors (MW, conjugation and NoL). Bar plot
shows principal component regression (PCR) analysis on regression coefficient (B) for
various LBL factor effects, while considering response variable (ML/M1) during analysis.
Results of test of significance on regression coefficient (B) (obtained from PCR analysis)
was performed by uncertainty tests and factor effects were considered insignificant if
uncertainty limits crosses the zero axes.
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A.3. Protease stability on LBLs of high MW polymers studying conjugation effect
A.3.1. PAA (MW 90,000 Da) materials - conjugation effect in 3-layered assemblies

Figure A-3.1: LBL protease stability. Effect of factor “extent of biotin conjugation” from
3-layered assemblies (NoL=3) developed of high MW (90,000 Da) polymer with varying
extent of biotinylation (Biotin- 0/5.55/7.1).
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A.3.2. PAA (MW 90,000 Da) materials - conjugation effect in 5-layered assemblies

Figure A-3.2: LBL protease stability. Effect of factor “extent of biotin conjugation” from
5-layered assemblies (NoL=5) developed of high MW (90,000 Da) polymer with varying
extent of biotinylation (Biotin-0/5.55/7.1).
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A.4. Protease stability on LBLs of high MW polymers studying layer effect
A.4.1. PAA (MW 90,000 Da) materials - layer effects in LBLs of unconjugated polymer

Figure A-4.1: LBL protease stability. Effect of factor “number of LBL layers (NoL)” from
high MW (90,000 Da) unconjugated polymer (Biotin-0 / PAA 90), where an
indistinguishable effect of number of assembly layers was noticed with increased
assembly layers.

93

A.4.2. PAA (MW 90,000 Da) materials - layer effects in LBLs of Biotin-5.5/PAA 90

Figure A-4.2: LBL protease stability. Effect of factor “number of LBL layers (NoL)” from
high MW (90,000 Da) biotinylated polymer (Biotin-5.55 / PAA 90) demonstrated
significant distinguishable barrier properties, where increased assembly layers resulted
in better chemical stability.
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A.5. Protease stability on LBLs of midrange MW polymers studying conjugation effect
A.5.1. PAA (MW 50,000 Da) materials - conjugation effects in 3-layered assemblies

Figure A-5.1: Protease stability on LBLs developed of mid-range MW (50,000 Da)
polymeric materials (PAA 50) studying effect of factor “extent of biotin conjugation”
from 3-layered assemblies (NoL=3) of varying extent of biotinylation (Biotin0/1.23/2.75). From plots it was observed, biotinylated polymers (Biotin-1.23/2.75) were
distinguishable from unconjugated polymers and showed improved chemical stability.
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A.5.2. PAA (MW 50,000 Da) materials - conjugation effects in 5-layered assemblies

Figure A-5.2: Protease stability on LBLs developed of mid-range MW (50,000 Da)
polymeric materials (PAA 50) studying effect of factor “extent of biotin conjugation”
from 5-layered assemblies (NoL=5) of varying extent of biotinylation (Biotin0/1.23/2.75). From plots it was observed, biotinylated polymers (Biotin-1.23/2.75) were
distinguishable from unconjugated polymers and showed improved chemical stability.
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A.5.3. PAA (MW 50,000 Da) materials - conjugation effects in 7-layered assemblies

Figure A-5.3: Protease stability on LBLs developed of mid-range MW (50,000 Da)
polymeric materials (PAA 50) studying effect of factor “extent of biotin conjugation”
from 7-layered assemblies (NoL=7) of varying extent of biotinylation (Biotin0/1.23/2.75). From plots it was observed, biotinylated polymers (Biotin-1.23/2.75) were
distinguishable from unconjugated polymers and showed improved chemical stability.
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A.6. Protease stability on LBLs of midrange MW polymers studying layer effect
A.6.1. PAA (MW 50,000 Da) materials - layer effects in LBLs of unconjugated polymer

Figure A-6.1: Protease stability on LBLs developed of mid-range MW (50,000 Da)
polymeric materials (PAA 50 studying effect of factor “number of LBL layers (NoL)”.
From LBLs of unconjugated polymer (Biotin-0 / PAA 50), it was observed the effects
were indistinguishable with increased number of assembly layers.
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A.6.2. PAA (MW 50,000 Da) materials - layer effects in LBLs of Biotin- 1.23 / PAA 50

Figure A-6.2: Protease stability on LBLs developed of mid-range MW (50,000 Da)
polymeric materials (PAA 50 studying effect of factor “number of LBL layers (NoL)”.
From LBLs of biotinylated polymer (Biotin-1.23 / PAA 50) a distinguishable effect with
increased number of assembly layers was observed.
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A.6.3. PAA (MW 50,000 Da) materials - layer effects in LBLs of Biotin- 2.75 / PAA 50

Figure A-6.3: Protease stability on LBLs developed of mid-range MW (50,000 Da)
polymeric materials (PAA 50) studying effect of factor “number of LBL layers (NoL)”.
From LBLs of biotinylated polymer (Biotin-2.75 / PAA 50) a distinguishable effect with
increased number of assembly layers was observed.
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A.6.4. Loss % from protease stability on LBLs of midrange MW (50,000 Da) polymers

Figure A-6.4: Protease stability on LBLs developed of mid-range MW (50,000 Da)
polymeric materials (PAA 50) studying loss % at M∞ for LBL assemblies developed of
various materials. From plots it was observed, biotinylated polymers (Biotin-1.23/2.75)
resulted in improved chemical stability with increased assembly layers.
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A.7. Multivariate analysis on LBL protease stability (uncertainty plots)

Figure A-7: PCR analysis on LBL protease stability studying LBL factor effects. Plot shows
principal component regression (PCR) analysis on regression coefficient (B) for various
LBL factors while considering variable (mass loss for t1/2 and t1/2) during analysis. Test of
significance on regression coefficient (B) was performed using uncertainty tests. LBL
factor effects with its uncertainty limit crossing over the zero axes were considered
insignificant.
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A.8. Salivary stability on LBLs of high MW polymers studying conjugation effect
A.8.1. PAA (MW 90,000 Da) materials - conjugation effect in 3-layered assemblies

Figure A-8.1: LBL salivary stability. Effect of factor “extent of biotin conjugation” from 3layered assemblies (NoL=3) developed of high MW (90,000 Da) polymer with varying
extent of biotinylation (Biotin- 0/5.55/7.1).
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A.8.2. PAA (MW 90,000 Da) materials - conjugation effect in 5-layered assemblies

Figure A-8.2: LBL salivary stability. Effect of factor “extent of biotin conjugation” from 5layered assemblies (NoL=5) developed of high MW (90,000 Da) polymer with varying
extent of biotinylation (Biotin- 0/5.55/7.1).
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A.9. Salivary stability on LBLs of high MW polymers studying layer effect
A.9.1. PAA (MW 90,000 Da) materials - layer effects in LBLs of unconjugated polymer

Figure A-9.1: LBL salivary stability. Effect of factor “number of LBL layers (NoL)” from
high MW (90,000 Da) unconjugated polymer (Biotin-0 / PAA 90).
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A.9.2. PAA (MW 90,000 Da) materials - layer effects in LBLs of Biotin- 5.55 / PAA 90

Figure A-9.2: LBL salivary stability. Effect of factor “number of LBL layers (NoL)” from
high MW (90,000 Da) biotinylated polymer (Biotin-5.55 / PAA 90) demonstrated
significant distinguishable barrier properties, where increased assembly layers resulted
in better chemical stability.
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A.10. Multivariate analysis on LBL salivary stability

Figure A-10: PCR analysis on LBL factors (molecular weight, conjugation and number of
layers). Plot shows principal component regression (PCR) analysis on regression
coefficient (B) for various LBL factors while considering variable (mass loss for t1/2 and
t1/2) during analysis. Test of significance on regression coefficient (B) was performed
using uncertainty tests. LBL factor effects with its uncertainty limit crossing over the
zero axes were considered insignificant.
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A.11. Main effects plot for LBL chemical stability for response “Mass loss% for t1/2”
LBL protease stability
Main Effects Plot for Mass Loss % for (t1/2)
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Figure A-11: LBL chemical stability. Plot shows main effect trends in LBL factors for
response “Mass loss% for t1/2“obtained from ANOVA plots demonstrates the trend
involved.
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LIST OF ABBREVIATIONS

ACN
ANOVA
AP
BMI
BSA
Conj
CREKA
CTC
COX
DNA
ECM
EDC
EGF
FGF
GA
GLM
HA
HABA
HNC
HPC
HSCT
IL
ITF
Laser
LBL
KGF
MES
MMP
MW
NCI
NF- κB
NHS
NoL
MW
OM
OMAS
PAA
p53
PBS
PC

Acetonitrile
Analysis of Variance
Activator protein
Body Mass Index
Bovine Serum Albumin
Conjugation (extent of biotinylation)
Cys-Arg-Glu-Lys-Ala
Common Toxicity Criteria
Cyclooxygenase
Deoxyribonucleic acid
Extracellular matrix
1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
Epidermal growth factor
Fibroblast growth factor
glycrrhetinic acid
Generalized Linear Model
Hyaluronic acid
4'-hydroxyazobenzene-2-carboxylic acid
Head and Neck Cancer
hydroxypropyl-cellulose
Hematopoietic Stem Cell Transplants
Interleukin
Intestinal trefoil factor
Light amplification by stimulated emission of radiation
Layer-by-Layer
Keratinocyte growth factor
2-(N-morpholino)ethanesulfonic acid
Matrix metalloproteinases
Molecular weight
National Cancer Institute
Nuclear factor- κB
N-hydroxysuccinimide
Number of layers
Molecular weight
Oral mucositis
Oral mucositis Assessment Scale
Poly(acrylic acid)
tumor protein 53
Phosphate-buffered saline
Principal Component
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PCA
PCR
PEM
PVP
rh
RIA
ROS
RP-HPLC
Sulfo-NHS
STAT3
TFA
TGF
TNF
UF
UWS
VEGF
WCCNR
WHO
WoS

Principal Component Analysis
Principal Component Regression
Polyelectrolyte Multilayers
polyvinyl pyrrolidone
recombinant human
Radioimmunoassay
Reactive Oxygen Species
Reverse Phase- High Performance Liquid Chromatography
N-hydroxysulfosuccinimide
Signal transducer and activator of transcription 3
Trifluoroacetic acid
Transforming growth factor
Tumor-necrosis factor
Ultrafiltration
Unstimulated Whole Saliva
Vascular endothelial growth factor
Western Consortium for Cancer Nursing Research
World Health Organization
Work of Separation
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